The drugmaker said on Tuesday the Department of Justice (DoJ) was closing the probe into the 18,000-patient study and no further action was planned. AstraZeneca views Brilinta as a potential $3.5 billion-a-year seller, but news last October that the DoJ was quizzing the company about the way it conducted the trial raised doubts over its medical value, causing sales to stall. The firm flagged up the promise of Brilinta in its defense against an abortive $118 billion takeover bid by Pfizer Inc earlier this year, although the drug registered only modest sales of $216 million in the first half of 2014. AstraZeneca also reported positive results on Tuesday with an experimental antibiotic called ceftazidime-avibactam as a treatment for hospitalized adult patients with complicated intra-abdominal infections.
Read More http://ift.tt/1pXsNls
No comments:
Post a Comment